Los Angeles Capital Management
ZNTL icon

Los Angeles Capital Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Los Angeles Capital Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-59,805
Closed -$181K – 1252
2024
Q4 		$181K Hold
59,805
– – ﹤0.01% 1068
2024
Q3 		$220K Sell
59,805
-23,912
-29% -$86.9K ﹤0.01% 1102
2024
Q2 		$342K Buy
83,717
+45,249
+118% +$505K ﹤0.01% 972
2024
Q1 		$606K Buy
+38,468
New +$529K ﹤0.01% 818

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Los Angeles Capital Management's ZNTL Position: Q1 2025 in Review

Los Angeles Capital Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2025, closing a stake of 59,805 shares — an estimated $181K sold.

Los Angeles Capital Management first reported a position in ZNTL in Q1 2024 and held it in 4 quarters. The position peaked at $606K in Q1 2024. 132 funds tracked by Wall St. Rank hold ZNTL as of Q1 2025.

  • Los Angeles Capital Management reported no remaining Zentalis Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Los Angeles Capital Management sold 59,805 Zentalis Pharmaceuticals shares in Q1 2025, an estimated $181K.
  • Los Angeles Capital Management first reported a position in Zentalis Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • Los Angeles Capital Management's Zentalis Pharmaceuticals position peaked at $606K in Q1 2024.
  • 132 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2025.

Based on Los Angeles Capital Management's 13F filing for Q1 2025, filed 5 May 2025.